Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Incredo (formerly DouxMatok) is a food technology company that has developed a patented sugar-based solution for efficient sugar reduction. Its flagship product, Incredo Sugar, uses a mineral carrier to deliver sugar directly to the taste receptors, allowing for a 30-50% reduction in sugar content without compromising taste or texture. The company's technology addresses global health challenges such as obesity and diabetes by enabling food manufacturers to create healthier products. Incredo partners with major food producers and provides a "plug-and-play" solution for various applications, including bakery, confectionery, and snacks. The company is headquartered in Israel and has established strategic partnerships with global sugar refiners and distributors to scale its impact. By optimizing the delivery of sucrose, Incredo enables a significant reduction in caloric intake while maintaining the sensory experience of traditional sugar.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on DouxMatok.